S&P 500   3,914.52 (-0.23%)
DOW   31,344.61 (-0.46%)
QQQ   293.24 (+0.72%)
AAPL   138.54 (-1.62%)
MSFT   255.02 (+0.37%)
FB   193.24 (+0.52%)
GOOGL   2,225.72 (-0.55%)
AMZN   2,170.58 (+1.32%)
TSLA   715.50 (+0.80%)
NVDA   173.92 (+2.68%)
BABA   88.10 (+0.90%)
NIO   16.70 (+5.50%)
AMD   98.14 (+1.93%)
CGC   5.92 (+5.90%)
MU   70.23 (-1.15%)
T   20.22 (-0.05%)
GE   76.20 (+1.33%)
F   13.09 (+2.43%)
DIS   104.01 (-0.28%)
AMC   13.12 (+2.82%)
PFE   50.73 (+0.65%)
PYPL   81.77 (+5.95%)
NFLX   184.66 (+4.22%)
S&P 500   3,914.52 (-0.23%)
DOW   31,344.61 (-0.46%)
QQQ   293.24 (+0.72%)
AAPL   138.54 (-1.62%)
MSFT   255.02 (+0.37%)
FB   193.24 (+0.52%)
GOOGL   2,225.72 (-0.55%)
AMZN   2,170.58 (+1.32%)
TSLA   715.50 (+0.80%)
NVDA   173.92 (+2.68%)
BABA   88.10 (+0.90%)
NIO   16.70 (+5.50%)
AMD   98.14 (+1.93%)
CGC   5.92 (+5.90%)
MU   70.23 (-1.15%)
T   20.22 (-0.05%)
GE   76.20 (+1.33%)
F   13.09 (+2.43%)
DIS   104.01 (-0.28%)
AMC   13.12 (+2.82%)
PFE   50.73 (+0.65%)
PYPL   81.77 (+5.95%)
NFLX   184.66 (+4.22%)
S&P 500   3,914.52 (-0.23%)
DOW   31,344.61 (-0.46%)
QQQ   293.24 (+0.72%)
AAPL   138.54 (-1.62%)
MSFT   255.02 (+0.37%)
FB   193.24 (+0.52%)
GOOGL   2,225.72 (-0.55%)
AMZN   2,170.58 (+1.32%)
TSLA   715.50 (+0.80%)
NVDA   173.92 (+2.68%)
BABA   88.10 (+0.90%)
NIO   16.70 (+5.50%)
AMD   98.14 (+1.93%)
CGC   5.92 (+5.90%)
MU   70.23 (-1.15%)
T   20.22 (-0.05%)
GE   76.20 (+1.33%)
F   13.09 (+2.43%)
DIS   104.01 (-0.28%)
AMC   13.12 (+2.82%)
PFE   50.73 (+0.65%)
PYPL   81.77 (+5.95%)
NFLX   184.66 (+4.22%)
S&P 500   3,914.52 (-0.23%)
DOW   31,344.61 (-0.46%)
QQQ   293.24 (+0.72%)
AAPL   138.54 (-1.62%)
MSFT   255.02 (+0.37%)
FB   193.24 (+0.52%)
GOOGL   2,225.72 (-0.55%)
AMZN   2,170.58 (+1.32%)
TSLA   715.50 (+0.80%)
NVDA   173.92 (+2.68%)
BABA   88.10 (+0.90%)
NIO   16.70 (+5.50%)
AMD   98.14 (+1.93%)
CGC   5.92 (+5.90%)
MU   70.23 (-1.15%)
T   20.22 (-0.05%)
GE   76.20 (+1.33%)
F   13.09 (+2.43%)
DIS   104.01 (-0.28%)
AMC   13.12 (+2.82%)
PFE   50.73 (+0.65%)
PYPL   81.77 (+5.95%)
NFLX   184.66 (+4.22%)
NASDAQ:EXAS

Exact Sciences (EXAS) Stock Forecast, Price & News

$53.86
+1.86 (+3.58%)
(As of 05/19/2022 03:10 PM ET)
Add
Compare
Today's Range
$50.44
$54.58
50-Day Range
$48.20
$76.23
52-Week Range
$46.15
$133.99
Volume
167,070 shs
Average Volume
2.66 million shs
Market Capitalization
$9.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
30 days | 90 days | 365 days | Advanced Chart
Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Exact Sciences logo

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$18.52 per share

Profitability

Net Income
$-595.63 million
Pretax Margin
-40.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
173,482,000
Market Cap
$9.48 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/26/2022
Today
5/19/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

133rd out of 1,418 stocks

Medical Laboratories Industry

2nd out of 32 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Exact Sciences
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings data on Tuesday, April, 26th. The medical research company reported ($1.04) earnings per share for the quarter, topping analysts' consensus estimates of ($1.12) by $0.08. The medical research company earned $486.57 million during the quarter, compared to the consensus estimate of $461.86 million. Exact Sciences had a negative trailing twelve-month return on equity of 21.82% and a negative net margin of 40.26%. During the same quarter in the prior year, the firm earned ($0.18) earnings per share.
View Exact Sciences' earnings history
.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2022 earnings guidance on Tuesday, April, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.99 billion-$2.03 billion, compared to the consensus revenue estimate of $2.01 billion.

What price target have analysts set for EXAS?

11 brokers have issued 12-month target prices for Exact Sciences' shares. Their forecasts range from $65.00 to $155.00. On average, they anticipate Exact Sciences' stock price to reach $106.00 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about Exact Sciences stock?
Here are some recent quotes from research analysts about Exact Sciences stock:
  • 1. According to Zacks Investment Research, "Exact Sciences has underperformed its industry in the past three months. The company exited the second quarter of 2021 with net loss wider than the Zacks Consensus Estimate. The widening of quarterly operating and net loss compared to the year-ago period is concerning. Revenues from the COVID-19 tests conducted during the quarter declined year over year. Further, Screening revenues registered a onetime downward adjustment of $12 million. The company also incurred significant operating loss on escalating costs and expenses. On a positive note, Exact Sciences reported better-than-expected revenues in the second quarter. Robust total revenue growth during the quarter, despite the pandemic-led headwinds, is impressive. The company’s legacy Screening business saw a significant improvement in revenues on Cologuard volume growth." (9/29/2021)
  • 2. The Goldman Sachs Group, Inc. analysts commented, " (6/3/2021)
Who are Exact Sciences' key executives?
Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 56, Pay $1.92M) (LinkedIn Profile)
  • Mr. Jeffrey T. Elliott CFA, Exec. VP, CFO & COO (Age 44, Pay $847.38k)
  • Mr. D. Scott Coward, Chief Legal Officer (Age 57, Pay $826.6k)
  • Mr. Graham P. Lidgard, Emeritus Chief Science Officer (Age 73, Pay $852.84k) (LinkedIn Profile)
  • Mr. Jake Orville, Gen. Mang. of Pipeline (Age 48, Pay $651.43k)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Jorge A. Garces Ph.D., Chief Science Officer (Age 50)
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP
  • Mr. Vic Parker, Head of Sales
What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.89%), ARK Investment Management LLC (8.23%), Sumitomo Mitsui Trust Holdings Inc. (3.23%), Nikko Asset Management Americas Inc. (2.94%), Baillie Gifford & Co. (2.48%) and Eminence Capital LP (1.28%). Company insiders that own Exact Sciences stock include Canada Pension Plan Investment, D Scott Coward, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Sarah Condella and Torsten Hoof.
View institutional ownership trends for Exact Sciences
.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Nicholas Investment Partners LP, Bank of Nova Scotia, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Baillie Gifford & Co., Ensign Peak Advisors Inc, and Advisor Group Holdings Inc.. Company insiders that have sold Exact Sciences company stock in the last year include Canada Pension Plan Investment, D Scott Coward, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella.
View insider buying and selling activity for Exact Sciences
or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Farallon Capital Management LLC, Vanguard Group Inc., New York State Common Retirement Fund, Ergoteles LLC, Zweig DiMenna Associates LLC, First Trust Advisors LP, and Swiss National Bank.
View insider buying and selling activity for Exact Sciences
or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $54.19.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $9.53 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595.63 million in net income (profit) each year or ($4.32) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at (608) 284-5700, via email at [email protected], or via fax at 608-284-5701.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.